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Vaccinia virus (VACV)-derived vectors are popular candidates for vaccination against diseases such as
HIV-1, malaria and tuberculosis. However, their genomes encode a multitude of proteins with
immunomodulatory functions, several of which reduce the immunogenicity of these vectors. Hitherto
only limited studies have investigated whether the removal of these immunomodulatory genes in com-
bination can increase vaccine efficacy further. To this end we constructed viruses based on VACV strain
Western Reserve (WR) lacking up to three intracellular innate immunomodulators (N1, C6 and K7). These
genes were selected because the encoded proteins had known functions in innate immunity and the dele-
tion of each gene individually had caused a decrease in virus virulence in the murine intranasal and intra-
dermal models of infection and an increase in immunogenicity. Data presented here demonstrate that
deletion of two, or three of these genes in combination attenuated the virus further in an incremental
manner. However, when vaccinated mice were challenged with VACV WR the double and triple gene
deletion viruses provided weaker protection against challenge. This was accompanied by inferior mem-
ory CD8+ T cell responses and lower neutralising antibody titres. This study indicates that, at least for the
three genes studied in the context of VACV WR, the single gene deletion viruses are the best vaccine vec-
tors, and that increased attenuation induced by deletion of additional genes decreased immunogenicity.
These data highlight the fine balance and complex relationship between viral attenuation and immuno-
genicity. Given that the proteins encoded by the genes examined in this study are known to affect specific
aspects of innate immunity, the set of viruses constructed here are interesting tools to probe the role of
the innate immune response in influencing immune memory and vaccine efficacy.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The poxvirus family is a diverse group of dsDNA viruses that
replicate in the cytoplasm of infected cells. The potential use of this
family, particularly the well-characterised vaccinia virus (VACV)
strains, as vaccine vectors has been under investigation since the
1980s [1]. VACV has many features that make it attractive for this
use; a large capacity for foreign gene expression, relative ease of
manipulation, and, importantly, induction of strong innate and
memory immune responses, including both cellular and humoral
arms [2]. Much research has focused on modified virus Ankara
(MVA) and NY-VAC because of their severe attenuation, and, at
least for MVA, the inability to replicate in most mammalian cells.These vectors are safe even in immunocompromised hosts [3,4],
which is of particular importance for vaccination against diseases
such as HIV-1, malaria and tuberculosis [2]. There is still a need
to improve the immunogenicity of these vectors, particularly
because large viral doses, repeated vaccination or prime-boost
regimes are required to achieve adequate correlates of protection
[5].
The host antiviral innate immune response provides a strong
selective pressure and, consequently, viruses have evolved a
plethora of mechanisms to counteract its effects. Engagement of
viral components with innate immune receptors activates
transcription factors including nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-jB) and interferon (IFN)
regulated factors (IRF)-3/7 that coordinate the production of
pro-inflammatory cytokines, chemokines and type I IFNs
(reviewed in [6,7]). Importantly this pro-inflammatory milieu
attracts professional antigen presenting cells to the site of
infection, providing an important link to the adaptive immune
response and the subsequent establishment of immune memory.
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dampening host innate responses (reviewed in [6]). For example,
nine intracellular NF-jB inhibitors have been identified and there
is evidence that more remain to be discovered [8]. In addition,
VACV encodes numerous IRF-3/7 inhibitors and multiple mecha-
nisms to counteract the actions of IFNs [6]. The mechanisms by
which innate immunity impacts successful vaccine design remain
incompletely understood. Importantly, recent data have demon-
strated that the deletion of several VACV immunomodulatory
genes individually enhances the immunogenicity of these vectors
(reviewed in [6,9]). Examples of such genes include the NF-jB inhi-
bitor N1 [10], the IRF-3/7 inhibitor C6 [11,12] and the dual NF-jB
and IRF-3/7 inhibitor K7 ([13] and Ren et al., unpublished data).
Proteins N1 and K7 have Bcl-2 folds [14,15] and C6 is predicted
to do so [16] and all are virulence factors [17–19].
Some studies have investigated the effect of deleting multiple
immunomodulatory genes from VACV vectors but so far have not
included an in-depth comparison of single gene deletions in isola-
tion versus deletion of genes in combination [13,20,21]. These
comparisons have also not always included challenge experiments,
instead measuring aspects of immunological memory that may
correlate with immune protection. This study therefore tested
whether the immunogenicity of VACV could be improved further
by deleting three intracellular innate immunomodulators in com-
bination (encoded by genes N1L, C6L and K7R) from VACV strain
Western Reserve (WR). These immunomodulators were selected
because their function in innate immunity was known, and
because deletion of each of these genes in isolation from VACV
WR increased immunogenicity, but decreased virulence. This study
shows that deletion of these three genes did not affect VACV
growth in vitro, but led to sequential attenuation of the virus in
two in vivo models. In challenge models, despite each individual
gene deletion enhancing immunogenicity, a virus lacking all three
genes was a poorer vaccine, accompanied by inferior memory T cell
responses and lower neutralising antibody titres. This illustrates
how the design of vaccines for optimal immunogenicity must con-
sider how the degree of attenuation impacts on the induction of
immunological memory.2. Materials and methods
2.1. Cells, viruses and mice
BSC-1 and CV-1 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM, GIBCO) supplemented with 10% (v/v) foetal
bovine serum (FBS) (Sigma-Aldrich, St. Louis, USA) and penicillin/
streptomycin (P/S, 50 lg/ml, Gibco, NY, USA). EL-4 cells were
grown in Roswell Park Memorial Institute medium (RPMI, GIBCO,
Paisley, UK) supplemented with 10% (v/v) FBS and 50 lg/ml P/S.
The deletion and revertant VACVs for N1L [17], C6L [18] and K7R
[19] were described previously. Female mice Balb/c and C57/B6
(6–8 weeks old) were purchased from Harlan (Blackthorn, United
Kingdom).2.2. Construction of Western Reserve recombinant viruses
Viruses were constructed using the transient dominant selec-
tion method [22] as described [18], using vDN1 [17] as a starting
point and plasmids Z11DC6 [18] and pSJH7-DK7 [19] to delete
C6L and K7R respectively. Z11 is a pCI-derived plasmid containing
the Escherichia coli guanylphosphoribosyl transferase (Ecogpt) gene
fused in-frame with the enhanced green fluorescent protein (EGFP)
gene under the control of the VACV 7.5 K promoter. Revertant
viruses were constructed by replacing the deleted genes in their
natural loci using plasmids Z11C6Rev [18] and pSJH7-K7 [19].The genotype of resolved viruses was analysed by PCR following
proteinase K-treatment of infected BSC-1 cells using primers that
anneal to the flanking regions of N1L, C6L and K7R [17–19]. Infec-
tious virus titres were determined by plaque assay on BSC-1 cells.
2.3. SDS-PAGE and immunoblotting
Infected BSC-1 cells were lysed in a cell lysis buffer containing
50 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol,
1% (v/v) Triton X100, 0.05% (v/v) NP40 supplemented with pro-
tease inhibitors (Roche). Samples were boiled for 5 min and then
subjected to SDS-PAGE. Primary antibodies were from the follow-
ing sources: mouse anti-a-tubulin (Upstate Biotech), mouse anti-
D8 mAb AB1.1 [23], rabbit-anti-N1 polyclonal antiserum [17],
rabbit-anti-C6 polyclonal antiserum [18] and rabbit-anti-K7 poly-
clonal antiserum [24]. Primary antibodies were detected with
goat-anti-mouse/rabbit IRdye 800CW infrared dye secondary anti-
bodies and membranes were imaged using an Odyssey Infrared
Imager (LI-COR Biosciences).
2.4. Plaque size analysis
BSC-1 cells were inoculated at approximately 50 plaque form-
ing units (p.f.u.) per well of a 6-well plate and stained with crystal
violet 3 days later [18]. The sizes of 20 plaques per well were mea-
sured using Axiovision acquisition software and a Zeiss AxioVert.
A1 inverted microscope as described [25].
2.5. Murine intranasal and intradermal models of infection
Female BALB/c mice (n = 5, 6–8 weeks old) were infected intra-
nasally (i.n.) with 5  103 p.f.u. of purified VACV strains. VACV was
purified from cytoplasmic extracts of infected cells by two rounds
of sedimentation through 36% (w/v) sucrose at 32,900g for 80 min.
Virus was resuspended in 10 mM Tris-HCl pH 9. Virus used for
infections was diluted in phosphate-buffered saline containing
1% bovine serum albumin and the titre of the diluted virus that
was used to infect mice was determined by plaque assay on the
day of infection. Mice were monitored daily to record body weight
and signs of illness as described [26,27]. Female C57BL/6 mice
(n = 5, 6–8 weeks old) were inoculated intradermally (i.d.) in both
ear pinnae with 104 p.f.u. and the resulting lesions were measured
daily as described [28,29]. For the challenge experiments, mice
that had been inoculated i.n. were challenged 6 weeks later and
mice that had been inoculated i.d. were challenged 4 weeks later,
i.n., with 5  106 p.f.u. of wild-type VACV WR.
2.6. Intracellular cytokine staining
Splenocytes were prepared as described [10] and incubated for
4 h with a C57BL/6-specific CD8+ VACV peptide B820–27 [30] or a
negative control CD8+ VACV peptide specific for BALB/c mice,
E3140–148 [31] at a final concentration of 0.1 lg/ml. After 1 h Golgi
stop (BD Biosciences) was added and the cells were incubated for a
further 3 h. Cells were then stained for CD8 and either IFNc or
TNFa and analysed by flow cytometry [10].
2.7. 51Cr release cytotoxic assay
Cytotoxic T lymphocyte (CTL) activity was assayed with a stan-
dard 51Cr-release assay using VACV-infected EL-4 cells as targets,
as described [32]. The percentage of specific 51Cr-release was cal-
culated as specific lysis = [(experimental release  spontaneous
release)/(total detergent release  spontaneous release)]  100.
The spontaneous release values were always <5% of total lysis.
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The neutralising titre of anti-VACV antibodies was calculated by
plaque assay on BSC-1 cells as described [10]. Neutralisation dose
50 (ND50) values represent the reciprocal of the serum dilution giv-
ing 50% reduction in plaque number compared with virus incu-
bated without serum.
2.9. Serum antibody titration by ELISA
The binding of serum antibodies to VACV-specific epitopes was
measured by enzyme-linked immunosorbent assay (ELISA) using
plates coated with lysates of VACV strain WR-infected cells that
had been treated with ultraviolet light and psoralen to inactivate
VACV infectivity as described [33,34]. Plates coated with bovine
serum albumin were used as a negative control. IgG end-point
titres were defined as the reciprocal serum dilutions giving twice
the average optical density values obtained with bovine serum
albumin.
2.10. Statistical analysis
Data were analysed using an un-paired Student’s t-test, with
Welch’s correction where appropriate, or a Mann–Whitney test
as indicated. Statistical significance is expressed as follows:
*P < 0.05, **P < 0.01, ***P < 0.001.
2.11. Ethics statement
This work was carried out in accordance with regulations of The
Animals (Scientific Procedures) Act 1986. All procedures werev∆N1 v∆∆ v∆∆∆
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3.1. Construction of a VACV strain WR lacking the innate
immunomodulatory genes N1L, C6L and K7R
To construct a virus lacking N1L, C6L and K7R, C6L was deleted
from a virus already lacking N1L (vDN1, [17]) by transient domi-
nant selection (see methods) yielding vDD, followed by the
removal of K7R yielding vDDD. As controls, a revertant virus where
the deleted gene was re-inserted back into its natural locus was
constructed at each stage (Fig. 1a). Deletion of C6L and K7R was
confirmed by PCR analysis of proteinase K-treated lysates of
infected BSC-1 cells using primers specific for these genes in addi-
tion to N1L and A49R as a control (Fig. 1b). The phenotype of the
resulting recombinant viruses was confirmed at the protein level
by immunoblotting of lysates from infected BSC-1 cells using antis-
era against N1, C6 and K7, as well as a monoclonal antibody against
VACV protein D8 as an infection control (Fig. 1c). Proteins N1, K7
and C6 are each non-essential for virus replication or spread in cell
culture [17–19] and measurement of the plaque size of mutants
lacking 2 or 3 of these genes confirmed that deletion of these genes
in combination did not affect viral spread in BSC-1 cells (Fig. 1d).
3.2. Deletion of N1L, C6L and K7R in combination attenuates the virus
sequentially in murine intradermal and intranasal models of infection
The N1L [17,35], C6L [18] and K7R [19] single deletion viruses
are attenuated in both the i.d. and i.n. models of murine infection,1N
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Fig. 2. Sequential attenuation of recombinant viruses. (a) The lesions induced by i.d. inoculation of C57BL/6 mice (n = 5) with 104 p.f.u. of the indicated viruses in both ear
pinnae were measured daily. Data are expressed as the mean lesion size (mm) ± SEM. (b and c) BALB/c mice (n = 5) were infected i.n. with 5  103 p.f.u. of the indicated
viruses and their weights (b) and signs of illness (c) were monitored daily. Weight data (b) are expressed as the percentage ± SEM of the mean weight of the same group of
animals on day 0. Signs of illness data (c) are expressed as the mean score ± SEM. Statistical analyses for data on the day p.i. indicated are in the tables on the right hand side
and were determined using the Student’s t-test. N/A indicates that data for this comparison could not be determined. Data are representative of at least 2 independent
experiments.
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side-by-side in the i.d. model, the level of attenuation was found to
be similar amongst the three single deletion viruses (Suppl.
Fig. 1a). In contrast, a virus lacking both N1 and C6 (vDD) was sig-
nificantly more attenuated than vDN1, and a virus lacking all three
immunodulators (vDDD) was attenuated further still (Fig. 2a),
indicating that the roles of these innate inhibitors in vivo is non-
redundant. The double deletion revertant (vDDR) and the triple
gene deletion revertant (vDDDR) control viruses behaved as
expected, demonstrating that the observed attenuation pheno-
types were due to specific genes deletions and not mutations else-
where in the viral genome (Suppl. Fig. 1b). Similar results were
obtained in the i.n. model of infection where deletion of C6 andK7 again led to sequential attenuation of the virus, as indicated
by reduced weight loss (Fig. 2b) and fewer signs of illness (Fig. 2c).
3.3. Deletion of N1L, C6L and K7R in combination does not enhance
vaccine potency
To determine whether the double and triple gene deletion
viruses have improved vaccine potency compared with the N1 sin-
gle deletion virus, mice were vaccinated i.d. and challenged i.n. one
month later with a lethal dose of wild-type VACV WR. As reported
[10], single deletion of N1 provided the mice with better protection
against challenge, indicated by significantly less weight loss over a
period of 10 days (Fig. 3a). However, vDD provided less protection
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Fig. 3. Vaccine potency of recombinant viruses. (a) Groups of five C57BL/6 mice were vaccinated by i.d. inoculation in both ear pinnae with 104 p.f.u. of the indicated viruses
and challenged i.n. 1 month later with 5  106 p.f.u. of wild-type WR and the resulting weight change was monitored daily. (b) Groups of five BALB/c mice that were
vaccinated i.n. with 5  103 p.f.u. of the indicated viruses were challenged i.n. 6 weeks later with 5  106 p.f.u. of wild-type VACV WR and the resulting weight change was
monitored daily. Data are expressed as the percentage ± SEM of the mean weight of the same group of animals on day 0. Statistical analyses for data on the days p.i. indicated
are in the tables on the right hand side and were performed using the Student’s t-test. All experiments were conducted at least twice and the data shown are representative.
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significance when compared to the WT virus on any one day)
and vDDD provided significantly less protection again (Fig. 3a).
Similar results were observed following challenge of mice that
were vaccinated i.n. (Fig. 3b). When compared head-to-head each
of the single deletion viruses enhanced vaccine potency to a similar
degree (Suppl. Fig. 2a) and the revertant control viruses behaved as
expected in challenge experiments (Suppl. Fig. 2b).3.4. The double and triple gene deletion viruses induce lower CTL
responses
To understand why vaccination with vDD or vDDD afforded
less protection than vDN1, CD8+ T cells responses one month
post-i.d. vaccination were analysed. To measure the cytolytic activ-
ity of VACV-specific T cells a chromium release cytotoxicity assay
was performed. The specific cytolytic activity of T cells from
vDN1-vaccinated mice was significantly higher than that from
vWT-vaccinated animals (Fig. 4a), corroborating recently pub-
lished findings [10]. Conversely, significantly lower VACV-specific
cytolytic activity of T cells was measured in vDD- or vDDD-vacci
nated mice. Interestingly, no significant difference in cytolytic
activity was observed between vDD and vDDD.
The release of cytokines by splenic CD8+ T cells that were stim-
ulated ex vivo with VACV peptides was also analysed by intracellu-
lar cytokine staining. In agreement with data published recently
[10], splenic CD8+ T cells from vDN1-vaccinated mice secreted
enhanced levels of IFNc (Fig. 4b) and TNFa (Fig. 4c) followingstimulation than cells from vWT-vaccinated mice. In contrast,
splenic CD8+ T cells from both vDD- and vDDD-vaccinated mice
secreted significantly less cytokines. Again, no significant difference
was observed between the double and triple gene deletion viruses.
3.5. Double and triple gene deletion viruses induce lower neutralising
antibody titres
The poorer immunogenicity of the double and triple gene dele-
tion viruses might also be due to altered antibody responses. To
investigate this possibility, sera were collected from mice one
month post-i.d. vaccination and the VACV-specific antibody titres
and VACV-specific neutralising titres were measured by ELISA
and plaque reduction neutralisation respectively. The titre of
VACV-specific antibodies measured by ELISA was not different
between the groups of vaccinated mice and good antibody levels
were induced in all cases (Fig. 5a). The same was not true, however,
when the titre of neutralising serum antibodies was measured by
plaque reduction neutralisation assay. In this case the ND50 of sera
from both the vDD- and vDDD-vaccinated mice was significantly
lower than that from both vWT and vDN1-vaccinated mice,
although there was no significant difference between the double
and triple gene deletion viruses (Fig. 5b).
4. Discussion
Inducing a robust innate immune response is an important step
to designing an immunogenic vaccine and this is often achieved by
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Fig. 4. CD8+ T cells responses one month post-vaccination. The activity of splenic T
cells from C57BL/6 mice (n = 5) was measured one month post-vaccination with
104 p.f.u. of the indicated viruses, or mock-vaccination with PBS in both ear pinnae.
(a) The cytolytic activity of splenic T-cells against VACV strain WR-infected EL-4
target cells was determined by 51Cr release assay. Data are expressed as percentage
specific lysis ± SEM. (b and c) The percentage of CD8+ T cells expressing IFNc (b) or
TNFa (c) was determined by intracellular cytokine staining. Data are expressed as
percentage ± SD. Statistical analyses were performed using the Student’s t-test.
*P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. The experiments were conducted
at least 3 times and the data shown are representative.
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of how the innate immune system impacts immune memory is
lacking and would greatly enhance our ability to rationally design
vaccines with enhanced immunogenicity profiles. VACV-based
vectors are popular candidates, however their genomes still encode
proteins with a known role in dampening the host innate immune
response, which may negatively impact their potential use as vac-
cine vectors. Indeed, the deletion of numerous VACV immunomod-
ulatory genes has been shown to enhance immunogenicity
including the chemokine-binding protein A41 [21,32], the IL-1b-
binding protein B15 [21,36], the inhibitor of MHC class II antigen
presentation A35 [37], the IL-18-binding protein C12 [38], the type
I (B18) and type II (B8) IFN-binding proteins [39], the IRF3/7 inhi-
bitor C6 [11,12], the NF-kB inhibitor and anti-apoptotic protein N1
[10], the dual NF-kB and IRF3/7 inhibitor K7 ([13] and Ren et al.,
unpublished results) and the TLR signalling inhibitor A46 [40].
Data presented here demonstrate that deletion of three of these
genes (N1L, C6L and K7R) in combination from VACV WR did not
further enhance the immunogenicity and in fact provided poorer
protection than the single gene deletion viruses. These data high-
light that in the context of a replicating vaccine vector there is a
fine balance between viral attenuation and immunogenic
potential.
Given that vDD and vDDD are sequentially more attenuated
than vDN1 (Fig. 2) they may have generated lower antigen levels
and/or been cleared more quickly by the host immune system
and hence induced a weaker adaptive response. The importance
of antigen availability for the formation of CD8+ T cell-dendritic cell
interaction kinetics and the ensuing memory response was demon-
strated recently [41]. Of further interest, the inferior CD8+ T cell
responses and neutralising antibody titres observed with vDD
and vDDD were not significantly different between these two
viruses, however vDDD provided worse protection than vDD in
the challenge studies (Fig. 3). These data may indicate that other
aspects of immune memory such as CD4+ T cells, or the recently
identified memory NK cells [42] may play an important role in
determining vaccine efficacy of VACV. Whether equivalent protec-
tion to WT or vDN1 vaccination could be achieved by increasing
the vaccination dose of vDD and vDDD warrants further
investigation.
A recent study using an MVA vector expressing HIV-1 antigens
(MVA-B) in the context of a DNA prime/MVA boost regime found
that the deletion of C6L and K7R in combination enhanced the mag-
nitude and quality of HIV-1-specific CD4+ and CD8+ T cell
responses in mice, as well as Env antibody levels compared to
the parental MVA-B vector and MVA-B lacking C6L alone [13].
These data demonstrate that in the context of a non-replicating
strain of VACV, the deletion of more than one immunomodulatory
gene may be beneficial. What is not clear from this study, however,
is whether these memory responses would have been achieved
with the deletion of K7R alone, because an MVA-B K7R single dele-
tion was not included. Furthermore, whether these correlates of
protection will translate to protection in an in vivo challenge model
remains to be determined. Another recent study, also based on an
MVA vector expressing HIV-1 antigens, found enhanced HIV-
specific CD4+ and CD8+ T cell responses as well as Env-specific anti-
body responses in rhesus macaques with a vector lacking 4
immunomodulatory proteins [20]. However again this vector was
not compared to single gene deletions and protection was not
determined by a challenge experiment.
Mounting evidence indicates an important role for type I IFN
[43,44] in vaccine immunogenicity and each of the proteins
selected for this study inhibits type I IFN production. Furthermore,
the importance of NF-jB in generating robust memory immune
responses was demonstrated recently for N1, an inhibitor of NF-
jB and apoptosis. By vaccinating mice with viruses encoding N1mutants that were competent for only one of these functions it
was demonstrated that the anti-NF-jB activity of N1 was impor-
tant for the enhanced protection observed with vDN1, with no
apparent contribution of its anti-apoptotic function [35]. These
types of studies demonstrate how viruses lacking innate
immunomodulators can be utilised as tools to further our under-
standing of the relationship between innate immunity and
immune memory, which will be important for future vaccine
design.
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Fig. 5. Humoral responses one month post-vaccination. Antibody responses of C57BL/6 mice (n = 5) were measured one month post-vaccination with 104 p.f.u. of the
indicated viruses in both ear pinnae. (a) Serum antibody end-point titres against VACV proteins were determined by ELISA. End-point titres were defined as the reciprocal
serum dilution giving twice the optical density obtained from BSA. (b) The neutralisation capacity of antibodies in the serum was assessed by plaque-reduction neutralisation
against VACV strain WR intracellular mature virus. The median value for each population is represented by a horizontal black bar. Statistical analyses were performed using
the Student’s t-test. **P < 0.01, ns: not significant. Experiments were conducted at least 3 times and representative data are shown.
R.P. Sumner et al. / Vaccine 34 (2016) 4827–4834 4833Conflicts of interest
The authors declare no conflicts of interest.Acknowledgements
This work was supported by Grants from the U.K. Medical
Research Council and the Wellcome Trust. GLS is a Wellcome Trust
Principal Research Fellow.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.08.
002.References
[1] Smith GL, Mackett M, Moss B. Recombinant vaccinia viruses as new live
vaccines. Biotechnol Genet Eng Rev 1984;2:383–407.
[2] Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors
against infectious diseases and tumors. Expert Rev Vacc 2011;10:1221–40.
[3] Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine
protects mice with and without immune deficiencies against pathogenic
vaccinia virus challenge. Proc Natl Acad Sci USA 2004;101:4590–5.
[4] Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and
NYVAC as gene delivery systems for vaccination against infectious diseases
and cancer. Curr Gene Ther 2008;8:97–120.
[5] Gilbert SC. Clinical development of modified vaccinia virus ankara vaccines.
Vaccine 2013;31:4241–6.
[6] Smith GL, Benfield CT, de Motes C Maluquer, Mazzon M, Ember SW, Ferguson
BJ, et al. Vaccinia virus immune evasion: mechanisms, virulence and
immunogenicity. J Gen Virol 2013;94:2367–92.
[7] Goubau D, Deddouche S, e Sousa C Reis. Cytosolic sensing of viruses. Immunity
2013;38:855–69.
[8] Sumner RP, de Motes C Maluquer, Veyer DL, Smith GL. Vaccinia virus inhibits
NF-kappaB-dependent gene expression downstream of p65 translocation. J
Virol 2014;88:3092–102.
[9] Garcia-Arriaza J, Esteban M. Enhancing poxvirus vectors vaccine
immunogenicity. Hum Vacc Immunother 2014;10:2235–44.
[10] Ren H, Ferguson BJ, de Motes C Maluquer, Sumner RP, Harman LE, Smith GL.
Enhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear
factor-kappaB inhibitor. Immunology 2015;145:34–49.
[11] Sumner RP, Ren H, Smith GL. Deletion of immunomodulator C6 from vaccinia
virus strain Western Reserve enhances virus immunogenicity and vaccine
efficacy. J Gen Virol 2013;94:1121–6.
[12] Garcia-Arriaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, Calandra T, et al.
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L
enhances memory HIV-1-specific T-cell responses. PLoS ONE 2011;6:e24244.
[13] Garcia-Arriaza J, Arnaez P, Gomez CE, Sorzano CO, Esteban M. Improving
adaptive and memory immune responses of an HIV/AIDS vaccine candidate
MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon
signaling pathways. PLoS ONE 2013;8:e66894.[14] Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA, et al.
Functional and structural studies of the vaccinia virus virulence factor N1
reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 2007;88:1656–66.
[15] Kalverda AP, Thompson GS, Vogel A, Schroder M, Bowie AG, Khan AR, et al.
Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its
interactions with human DEAD box RNA helicase DDX3. J Mol Biol
2009;385:843–53.
[16] Graham SC, Bahar MW, Cooray S, Chen RA, Whalen DM, Abrescia NG, et al.
Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to
inhibit NF-kappaB rather than apoptosis. PLoS Pathog 2008;4:e1000128.
[17] Bartlett N, Symons JA, Tscharke DC, Smith GL. The vaccinia virus N1L protein is
an intracellular homodimer that promotes virulence. J Gen Virol
2002;83:1965–76.
[18] Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, Bourke NM, et al.
Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor
proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 2011;7:
e1002247.
[19] Benfield CT, Ren H, Lucas SJ, Bahsoun B, Smith GL. Vaccinia virus protein K7 is a
virulence factor that alters the acute immune response to infection. J Gen Virol
2013;94:1647–57.
[20] Garber DA, O’Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, et al.
Deletion of specific immune-modulatory genes from modified vaccinia virus
Ankara-based HIV vaccines engenders improved immunogenicity in rhesus
macaques. J Virol 2012;86:12605–15.
[21] Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. Immunogenic
profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four
HIV-1 antigens and potentiation by specific gene deletions. PLoS ONE 2010;5:
e12395.
[22] Falkner FG, Moss B. Escherichia coli gpt gene provides dominant selection for
vaccinia virus open reading frame expression vectors. J Virol
1988;62:1849–54.
[23] Parkinson JE, Smith GL. Vaccinia virus gene A36R encodes a M(r) 43–50 K
protein on the surface of extracellular enveloped virus. Virology
1994;204:376–90.
[24] Schroder M, Baran M, Bowie AG. Viral targeting of DEAD box protein 3 reveals
its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J
2008;27:2147–57.
[25] Ferguson BJ, Benfield CT, Ren H, Lee VH, Frazer GL, Strnadova P, et al. Vaccinia
virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol
2013;94:2070–81.
[26] Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M. Biological
characterization of recombinant vaccinia viruses in mice infected by the
respiratory route. J Gen Virol 1990;71:2761–7.
[27] Alcami A, Smith GL. A soluble receptor for interleukin-1 beta encoded by
vaccinia virus: a novel mechanism of virus modulation of the host response to
infection. Cell 1992;71:153–67.
[28] Tscharke DC, Smith GL. A model for vaccinia virus pathogenesis and immunity
based on intradermal injection of mouse ear pinnae. J Gen Virol
1999;80:2751–5.
[29] Tscharke DC, Reading PC, Smith GL. Dermal infection with vaccinia virus
reveals roles for virus proteins not seen using other inoculation routes. J Gen
Virol 2002;83:1977–86.
[30] Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, et al.
Identification of poxvirus CD8+ T cell determinants to enable rational design
and characterization of smallpox vaccines. J Exp Med 2005;201:95–104.
[31] Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, Moss DJ, et al. Poxvirus
CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol
2006;80:6318–23.
[32] Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL. Deletion of gene
A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol
2006;87:29–38.
4834 R.P. Sumner et al. / Vaccine 34 (2016) 4827–4834[33] Law M, Putz MM, Smith GL. An investigation of the therapeutic value of
vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol
2005;86:991–1000.
[34] Putz MM, Midgley CM, Law M, Smith GL. Quantification of antibody responses
against multiple antigens of the two infectious forms of Vaccinia virus
provides a benchmark for smallpox vaccination. Nat Med 2006;12:1310–5.
[35] de Motes C Maluquer, Cooray S, Ren H, Almeida GM, McGourty K, Bahar MW,
et al. Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1
occur via distinct binding surfaces and make different contributions to
virulence. PLoS Pathog 2011;7:e1002430.
[36] Staib C, Kisling S, Erfle V, Sutter G. Inactivation of the viral interleukin 1beta
receptor improves CD8+ T-cell memory responses elicited upon immunization
with modified vaccinia virus Ankara. J Gen Virol 2005;86:1997–2006.
[37] Rehm KE, Roper RL. Deletion of the A35 gene from modified vaccinia virus
ankara increases immunogenicity and isotype switching. Vaccine
2011;29:3276–83.
[38] Falivene J, Zajac MP Del Medico, Pascutti MF, Rodriguez AM, Maeto C,
Perdiguero B, et al. Improving the MVA vaccine potential by deleting the viral
gene coding for the IL-18 binding protein. PLoS ONE 2012;7:e32220.[39] Gomez CE, Perdiguero B, Najera JL, Sorzano CO, Jimenez V, Gonzalez-Sanz R,
et al. Removal of vaccinia virus genes that block interferon type I and II
pathways improves adaptive and memory responses of the HIV/AIDS vaccine
candidate NYVAC-C in mice. J Virol 2012;86:5026–38.
[40] Perdiguero B, Gomez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, et al.
Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR
signalling, is an effective approach to enhance the immunogenicity in mice of
the HIV/AIDS vaccine candidate NYVAC-C. PLoS ONE 2013;8:e74831.
[41] Henrickson SE, Perro M, Loughhead SM, Senman B, Stutte S, Quigley M, et al.
Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics
and memory fate decisions. Immunity 2013;39:496–507.
[42] Gillard GO, Bivas-Benita M, Hovav AH, Grandpre LE, Panas MW, Seaman MS,
et al. Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer
protection against vaccinia virus challenge in the absence of adaptive
lymphocytes. PLoS Pathog 2011;7:e1002141.
[43] Le Bon A, Tough DF. Links between innate and adaptive immunity via type I
interferon. Curr Opin Immunol 2002;14:432–6.
[44] Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type
I interferon. Immunology 2011;132:466–74.
